ProKidney signs SPAC merger deal with Social Capital Suvretta
ProKidney delivers disease-altering autologous cell therapy to treat chronic kidney disease.
deal
Latest in
deal
Lilly and Evotec enter partnership for metabolic disease drug discovery
Evotec will receive undisclosed upfront, milestone and tiered royalty payments totalling up to $1bn.
Abbisko Therapeutics and Lilly partner to develop new molecules
Abbisko is eligible to receive up to $258m in milestone payments from Lilly.
GSK rejects Unilever’s $68.4bn offer for Consumer Healthcare business
GSK noted that the bids ‘fundamentally undervalued’ the Consumer Healthcare business.
BenevolentAI and AstraZeneca expand drug discovery partnership
The companies collaborated initially in 2019 to use AI and machine learning to develop new therapies for CKD and IPF.
ABL Bio and Sanofi partner to develop antibody for Parkinson’s disease
ABL Bio will receive $985m in milestone payments from Sanofi in addition to royalties on the net sales of the…
BMS and Century partner for allogeneic cell therapy development
Century will receive payments for programme commencement as well as aggregate milestone payment for the four programmes.
Sanofi and Exscientia to develop AI-driven cancer and immunology medicines
Exscientia is eligible to receive milestone payments of up to nearly $5.2bn from Sanofi in the future.